Sat, Dec 27, 2014, 5:58 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Yippy, Inc. Message Board

garysnoop1 308 posts  |  Last Activity: Dec 24, 2014 4:27 PM Member since: Oct 16, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • garysnoop1 by garysnoop1 Sep 30, 2014 9:26 AM Flag

    Take a position charged with the development of Inovio’s portfolio of oncology and infectious disease .Why?? As stated, She recently served at Boehringer Ingelheim. and most of all Merck .So why would she go with a back woods Pharmaceutical As INOVIO..Well I'm shure after going over every avbl. document,trial,test and potential, partnership she felt comfortable in all seen to make the move.To me this speaks volumes.Time is on our side..90 employees are poised for something.The finances are in place and if you remember they are building the 10,000 sq, ft, building to house "something "You can only move so fast,and they are doing just fine..

  • CEO and President Joseph Kim stated that one synthetic Ebola vaccine in progress has shown opening success in beating back the deadly virus. The firm is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases.

  • This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the medical space as it currently has a Zacks Industry Rank of 55 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

    Meanwhile, Inovio Pharmaceuticals is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

    In fact, over the past month, current quarter estimates have narrowed from a loss of 12 cents a share to a loss of 3 cents a share, while current year estimates have narrowed from a loss of 72 cents per share to a loss of 60 cents per share. This has helped INO to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position.

    So, if you are looking for a decent pick in a strong industry, consider Inovio Pharmaceuticals. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

  • Chart annalists are watching the end of a five wave pattern with solid volume to the up side.Usually indicates a break out We need to break thru 11.50 with strong volume of which we have already been showing to date, volume has steadily been building with minimal sales on the down side..This is NO time to daytrade..........or be short..

    Sentiment: Strong Buy

  • Oct. 9, 2014 1:32 PM ET | About: Inovio Pharmaceuticals, Inc. (INO) by: Biotech Research Group

    Disclosure: The author is long INO. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article. (More...)


    •Inovio's DNA-based, proprietary technology can demonstrate robust response rates.
    •Understanding the long-term potential for Inovio's Ebola participation.

    Understanding the intricacies of the companies that we invest in can go a long way in helping us understand why certain companies tend to participate in sector rallies while others stand idle or are left behind during sector appreciations. As a long-term investor in Inovio Pharmaceuticals (NASDAQ:INO), I have watched my investment participate on both sides of the equation, appreciating while other sector stocks languish and depreciating at times when the sector is rallying.

    But as much as Inovio can be compared to others, the truth is that the science behind what Inovio is trying to accomplish in clinical trials is quite different from many of its peers. Inovio differentiates itself not only by its science, but has also published clinical data demonstrating its emergence as a next generation pharmaceutical company.

    The most recent indication that promotes these differences was evidenced during an interview by CNBC's Melissa Lee. The interview questioned Dr. Joseph Kim, CEO of Inovio Pharmaceuticals, and focused on Inovio's leadership role in current Ebola trials. The televised interview highlighted that Inovio has demonstrated, in animal trials, a 100% effective vaccine that provided protection against the Ebola virus when introduced to the test animal. The results indicate an early model for a preventative vaccine that, like other Inovio studies, had no visible safety or adverse side effects. The results of this study were published in a peer reviewed and vetted article.

    When pressed about the science, Dr. Kim responded that the strongest aspect of the Inovio vaccine model is that the SynCon technology currently being used in the clinical trial is a DNA-based, computer generated model, which is designed to replicate the virus and attack the disease based on certain amino acid response.

    Sentiment: Strong Buy

  • Reply to


    by terry.booth1 Nov 9, 2014 1:04 PM
    garysnoop1 garysnoop1 Nov 9, 2014 6:54 PM Flag

    Terry..I understand pretty much what your thinking, but everything doesn't hang on tomorrow's news ,next week or month what ever it takes time wise, things will workout. The one thing I look at, is in all the time since this adventure began, we haven't had a setback or bad news to speak of. Seems like slow and steady is winning the least for most of us.

    Sentiment: Strong Buy

  • I would wounder if a word some what like "were still on track "or something at all to stop the bleeding may be in order.It.s been a down hill run since the R/S and I believe a word from INOVIO might be in order. As we support INOVIO we have trust and belief ,once and a while like times like this it needs to be bolstered. Please make this a consideration

  • and INOVIO coming to the forefront, don't be surprised to see it on the table..

  • conservative, we could see results not long down the road.If at that point it is fast-tracked, the sky is the limit..

    Sentiment: Strong Buy

  • PLYMOUTH MEETING, Pa. – December 17, 2014 – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Zane Yang, M.D. as Vice President, Clinical Development, Oncology. In this position, he will be responsible for advancing Inovio’s oncology portfolio of DNA immunotherapies through clinical trials to commercialization. He will report to Dr. Mark Bagarazzi, Inovio’s Chief Medical Officer.

    Inovio is planning a phase III trial for its immunotherapy for a pre-cancer, known as cervical dysplasia, which met its endpoints in a recent phase II trial. The company is in or about to move into phase I trials for numerous cancers including prostate, cervical, breast, lung, head and neck and pancreatic cancers.

    Dr. Yang joins Inovio from Janssen Pharmaceuticals, a unit of Johnson & Johnson, where he was Director, Oncology Medical Affairs in the U.S. Dr. Yang led the prostate cancer and solid tumor therapeutic area including development and commercialization of Zytiga®, for the treatment of metastatic castration-resistant prostate cancer. Prior to Janssen, he was Director of Global Medical Affairs and Clinical Development at Novartis Oncology, and Director of Clinical Development at Merck & Co.

    Dr. J. Joseph Kim, President & CEO of Inovio, said, “Zane is a highly regarded and accomplished executive and clinical researcher whose experience in the global cancer market makes him exceptionally qualified to lead clinical development in oncology at Inovio. There’s a new wave of cancer therapeutics coming, products that enhance the body’s immune system to fight and prevent cancer. Inovio is proud to be a leader in this new paradigm of products and Dr. Yang’s leadership will play a critical role as we move forward.”

    Dr. Yang, who earned his M.D. at Beijing Medical University, was a Fellow at Emory University’s Winship Cancer Institute and the Wistar Institute. Before transitioning to the pharmaceutical industry he was an associate professor at the University of Virginia Medical Center.

  • Kim is president of Inovio Pharmaceuticals in Plymouth Meeting. The company has developed a vaccine to protect against the deadly Ebola virus. It's been tested on animals, showing it is safe.

    "We're able to protect 100% from both death as well as sickness," Kim said.

    Unlike other vaccines, this one doesn't use a virus.

    "What conventional vaccine folks have to do is get a hold of the Ebola virus and use different parts to make it," he explained.

    At Inovio researchers use a computer, take the genetic code of the virus, then make a synthetic vaccine. Kim says to manufacture it, they use a similar fermentation process as what's used to brew beer.

    It can be made much faster than conventional vaccines. No one seems to know this company at all...TILL NOW !

    Kim says, "10,000 doses will take about a month."

  • garysnoop1 garysnoop1 Oct 13, 2014 1:36 PM Flag

    Also send it to the Pennsylvania Senators.Inovio is in their state incase they didn't know what is in their back yard..

  • garysnoop1 garysnoop1 Nov 9, 2014 11:58 AM Flag

    Bingo..It's under oral presentation..DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial
    Laurent Humeau1*, Cornelia Trimble2, Matthew Morrow1, Xuefei Shen1, Michael Dallas1, David Weiner3, Jean Boyer3, Jian Yan1, Kimberly Kraynyak1, Albert Sylvester1, Mary Giffear1, Kathy Marcozzi-Pierce1, Divya Shah1, Kate Broderick1, Amir Khan1, Jessica Lee1, Niranjan Sardesai1, Mark Bargarazzi1 and the HPV-003 Protocol team1

    * Corresponding author: Laurent Humeau
    Author Affiliations
    1 Inovio Pharmaceuticals, USA

    2 Johns Hopkins, Baltimore MD, USA

    3 Perelman School of Medicine University of Pennsylvania, PA, USA

  • Reply to

    Well..we were thrown the morning bone...again..

    by garysnoop1 Oct 1, 2014 9:48 AM
    garysnoop1 garysnoop1 Oct 2, 2014 9:43 AM Flag

    This stock is being played big it up in the AM...sell...Buy it back in the afternoon like clockwork..

  • Or do nothing..It's your money..

    Sentiment: Strong Buy

  • Reply to

    Massive market Manipulation

    by siriusjaz Oct 14, 2014 10:17 AM
    garysnoop1 garysnoop1 Oct 14, 2014 10:21 AM Flag

    governing government is owned by big money..that's it. I don't see much I like in the Good old USA anymore..sad.

  • garysnoop1 garysnoop1 Oct 19, 2014 3:27 PM Flag

    Great find thanks..This should more than support the price Monday...lets bump it up..when needed. The science will take care of it's self..

    Sentiment: Strong Buy

  • garysnoop1 garysnoop1 Oct 11, 2014 4:30 PM Flag

    Start sending this out..Very strong buy..

    Sentiment: Strong Buy

  • This will take off and it will cost a lot to get back in..I'm shure a lot of you have been there..I have. I'm not going to let it happen here..I'm staying..

    Sentiment: Strong Buy

  • First let me say their reply was very prompt and somewhat open.
    It is a resetting of priorities. I can tell you that Roche terminated the agreement. These things aren't typically described in great detail, so there is not more that I can tell you.

    The prostate and the hepatitis B product development groups are separate groups, however, and the hepatitis B program is still moving forward.

0.290.00(+0.03%)Dec 26 9:47 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
Tesla Motors, Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
Lowe's Companies Inc.
NYSEFri, Dec 26, 2014 4:02 PM EST